Navigation Links
Evaluating That Thing On Your Skin Just Got a Whole Lot Easier
Date:11/5/2013

BOSTON, Nov. 5, 2013 /PRNewswire/ -- Olay® facial cream's famous motto was "Love the skin you're in." We should, since our largest organ does so much for us. Skin acts as a waterproof insulating shield, guarding the body against extremes of temperature, damaging sunlight and harmful chemicals. It exudes antibacterial substances that prevent infection, and manufactures vitamin D for converting calcium into healthy bones. Skin is also a huge sensor, packed with nerves for keeping the brain in touch with the outside world. But loving the skin we're in is actually easier said than done, because of the ever-present possibility of skin cancer. 

This is an understandable concern, with the American Cancer Society reporting there are more than 3.5 million skin cancers diagnosed each year—more than all other cancers combined. This makes us leery of every suspicious lump, mole, skin tag or discoloration on the body. We also worry that our doctor might overlook a potentially cancerous lesion; or if not, that the biopsy will be painful and leave us with a visible scar. Scarring does happen, even if that suspicious lesion is benign.

Is there an answer to this all-too-prevalent dilemma?

Now there is, thanks to a remarkable advance in medical instrumentation. Based in Boston and Rochester, Caliber Imaging & Diagnostics (Caliber I.D.) is a leader in noninvasive optical biopsies—i.e., its technology can capture high-resolution images providing doctors with cellular views at varying depths under the skin, enabling an accurate real-time diagnosis. Caliber I.D. has created and is already marketing a suite of its FDA-cleared devices, known as VivaScope® confocal imaging systems.

Since there is no cutting involved with VivaScope, there is also no possibility of infection or scarring. Obtaining an image takes just a few minutes so the doctor can make a determination at the bedside, or the image can be transferred within minutes through the company's VivaNet® system, so that a pathologist can diagnose it remotely.

Enthusiastic users include prestigious hospitals and many other leading academic institutions, private physicians' practices and Fortune 500 companies. As CEO L. Michael Hone explains, "The VivaScopes allow physicians to nondestructively examine tissue to determine whether it is responding to therapy; or, when surgery has been performed, to quickly and efficiently examine the skin surrounding the excised cancerous lesion."

Hone adds, "Consult your healthcare provider immediately when you spot anything you think might be questionable. When you see your doctor, you might want to ask if he or she has a VivaScope, the noninvasive way to biopsy your skin."  

For more on this major advance, visit www.caliberid.com, who paid for the writing and dissemination of this release.

Contact: Laura Radocaj, Dian Griesel Int'l., 212.825.3210

 


'/>"/>
SOURCE Caliber I.D.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
2. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
3. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
5. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
6. Study Showcases Effective Approaches for Evaluating the Performance of Executives who Handle Managed Markets Accounts
7. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
8. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
9. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
10. AtheroMed Announces Completion of Patient Enrollment in the EASE Study Evaluating the Phoenix Atherectomy System in Treating PAD
11. AtheroMed Announces Results Of The EASE Study Evaluating The Phoenix Atherectomy System In Treating Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)...   , Study met both ... in , Excellent plus Good ... of the ascending colon   ,      ... announced new positive data from the phase III MORA study for ... litre PEG with ascorbate. The study met both primary endpoints showing ...
(Date:5/24/2016)... 2016 ARANZ Medical  Ltd a ... sector, has been named the Coretex Hi-Tech Emerging Company of ... Dr Bruce Davey , CEO of ARANZ Medical ... really good to be recognised for the work we are ... used in 35 countries around the world from Sub-Saharan Africa ...
(Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... ... CloudLIMS, joins an elite number of companies that have earned a spot on ... CIOReview. , In a deliberate session with the honorary industrial experts, a list of ... with. The positioning is based on evaluation of CloudLIMS’ specialties in Automated Sample Management ...
(Date:5/25/2016)... ... 25, 2016 , ... DKT International, one of the largest ... pleased to release their 2015 global impact data. In 2015, DKT served over ... deaths and 3.8 million unsafe abortions across 21 countries worldwide. , “We ...
(Date:5/25/2016)... Mexico (PRWEB) , ... May 25, 2016 , ... Casa ... the restorative properties of precious stones to complement its new wellness suites . ... two floors and feature a plethora of special services and insuite amenities, from a ...
(Date:5/25/2016)... ... ... more than fifty years, we've suffered whiplash as each new scientific study seemed to contradict ... nutritional advice – advice that was supposed to keep us healthy and slim. And what ... are considered to be overweight and more than 1 in 3 adults are considered to ...
(Date:5/25/2016)... ... 25, 2016 , ... Researchers from SUNY State College of Optometry won the ... visual evoked potential and human attention. The article, VEP and Human Attention: Translation ... ERG and VEP Vision Testing System (Diopsys, Inc., Pine Brook, NJ) to record ...
Breaking Medicine News(10 mins):